Claus Werenberg Marcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claus Werenberg Marcher has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Anne Stidsholt Roug
Department of Haematology Aarhus University Hospital Aarhus Denmark
4 shared publications - Daniel Tuyet Kristensen
Aarhus University Hospital, Aarhus, Denmark
4 shared publications - Marianne Tang Severinsen
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
4 shared publications - Rasmus Froberg Brøndum
Center for Clinical Data Science, Department of Clinical Medicine, Aalborg University and Research, Education and Innovation, Aalborg University Hospital, Aalborg, Denmark
4 shared publications - Claudia Schöllkopf
Department of Hematology, Herlev Hospital, Herlev, Denmark
3 shared publications Andreas Due Ørskov
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Prediction of overall survival in acute myeloid leukemia using supervised machine learning
- 28 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessPrediction of overall survival in acute myeloid leukemia using supervised machine learning
- Open Access
- 28 August 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-5
Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy
- 28 August 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-5
Open AccessOutcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy
- Open Access
- 21 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1416-1424
Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline‐containing chemotherapy: A population‐based matched cohort study
Summary: Anthracycline‐containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline‐containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow‐up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02–32.1) after 3 months to 2.68 (95% CI: 1.67–4.30) after 15 years. The risk of non‐CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61–12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non‐CHF CVD. In summary, AML patients treated with anthracycline‐containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.
- 21 July 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1416-1424
Open AccessCardiotoxicity in patients with acute myeloid leukaemia following anthracycline‐containing chemotherapy: A population‐based matched cohort study
Summary: Anthracycline‐containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline‐containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow‐up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02–32.1) after 3 months to 2.68 (95% CI: 1.67–4.30) after 15 years. The risk of non‐CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61–12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non‐CHF CVD. In summary, AML patients treated with anthracycline‐containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.
- Open Access
- 25 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 573-582
Venetoclax‐based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy
Background: The treatment of relapsed or refractory (R/R) acute myeloid leukaemia (AML) remains challenging and outcomes extremely poor. The introduction of venetoclax has transformed the treatment of AML and emerging data suggest that venetoclax‐based therapy may enforce salvage treatment.Materials and Methods: In this nationwide Danish retrospective study, we analysed treatment outcomes of venetoclax‐based salvage treatment for R/R AML between 2019 and 2022. Only venetoclax‐naive patients who had previously received treatment with intensive chemotherapy therapy were included.Results: The cohort consisted of 43 R/R patients with a median age of 57 years. Nine (20.9%) were primary refractory and 34 (79.1%) patients had relapsed, including 21 after previous allogeneic stem cell transplantation. The overall response rate was 76.2% including 61.9% with composite complete remission (CRc: CR + CRi). Among CRc‐responders with information on measurable residual disease (MRD), 8/13 (61.5%) obtained an MRD‐negativity response. The overall survival was 9.3 months for all patients with an estimated 1‐year overall survival of 34%. For CRc‐responders the median overall survival was 13.3 months, and the median relapse‐free survival was 12.8 months.Conclusion: Venetoclax‐based salvage treatment for R/R AML produced high response rates; however, for most patients the response was of limited duration. This study is limited by an observational design and prone to selection bias.
- 25 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 573-582
Open AccessVenetoclax‐based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy
Background: The treatment of relapsed or refractory (R/R) acute myeloid leukaemia (AML) remains challenging and outcomes extremely poor. The introduction of venetoclax has transformed the treatment of AML and emerging data suggest that venetoclax‐based therapy may enforce salvage treatment.Materials and Methods: In this nationwide Danish retrospective study, we analysed treatment outcomes of venetoclax‐based salvage treatment for R/R AML between 2019 and 2022. Only venetoclax‐naive patients who had previously received treatment with intensive chemotherapy therapy were included.Results: The cohort consisted of 43 R/R patients with a median age of 57 years. Nine (20.9%) were primary refractory and 34 (79.1%) patients had relapsed, including 21 after previous allogeneic stem cell transplantation. The overall response rate was 76.2% including 61.9% with composite complete remission (CRc: CR + CRi). Among CRc‐responders with information on measurable residual disease (MRD), 8/13 (61.5%) obtained an MRD‐negativity response. The overall survival was 9.3 months for all patients with an estimated 1‐year overall survival of 34%. For CRc‐responders the median overall survival was 13.3 months, and the median relapse‐free survival was 12.8 months.Conclusion: Venetoclax‐based salvage treatment for R/R AML produced high response rates; however, for most patients the response was of limited duration. This study is limited by an observational design and prone to selection bias.
- 12 March 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (8) , 2014-2017
Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001–2016: a Danish nationwide cohort study
In a recent study by our group we showed a disappointing absence of survival improvement among elderly acute myeloid leukemia (AML) patients from 2001 until 2016. The importance of which is undersc...
- 12 March 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (8) , 2014-2017
Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001–2016: a Danish nationwide cohort study
In a recent study by our group we showed a disappointing absence of survival improvement among elderly acute myeloid leukemia (AML) patients from 2001 until 2016. The importance of which is undersc...
- 12 November 2019
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (2) , 627-631
Malignant but not maleficent: acute leukaemia as a possible explanation of disease and death in vampire victims
A considerable amount of research has been put into the explanation of the origin of the vampire myth by focussing on possible symptoms of the vampire; however, very little attention has been given to the victims.
- 12 November 2019
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (2) , 627-631
Malignant but not maleficent: acute leukaemia as a possible explanation of disease and death in vampire victims
A considerable amount of research has been put into the explanation of the origin of the vampire myth by focussing on possible symptoms of the vampire; however, very little attention has been given to the victims.
- Open Access
- 1 February 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (2) , 314-323
Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study
- 1 February 2018
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 24 (2) , 314-323
Open AccessImpact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study